APO Research
Talk to an analyst

APO RESEARCH · REPORT

Amyotrophic Lateral Sclerosis (ALS) Treatment

Amyotrophic lateral sclerosis (ALS) is also known as Lou Gehrig’s disease or Maladie De Charcot, it is a neurological disease that causes nerve cells to gradually break down and die.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Amyotrophic lateral sclerosis (ALS) is also known as Lou Gehrig’s disease or Maladie De Charcot, it is a neurological disease that causes nerve cells to gradually break down and die.

The cause is not known in 90% to 95% of cases. The remaining 5–10% of cases are inherited from a person's parents. About half of these genetic cases are due to one of two specific genes. The underlying mechanism involves damage to both upper and lower motor neurons. The diagnosis is based on a person's signs and symptoms, with testing done to rule out other potential causes.

Selected research

Market Outlook & Growth Opportunities

Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Outlook and Growth Opportunities 2026

21 December 2025194 pages

Choose your research edition.

Industry ResearchAmyotrophic Lateral Sclerosis (ALS) Treatment Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Amyotrophic Lateral Sclerosis (ALS) Treatment Industry Growth and Trends Forecast to 203287 pages · $3,450 USDMarket StructureGlobal Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032189 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Amyotrophic Lateral Sclerosis (ALS) Treatment Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Amyotrophic Lateral Sclerosis (ALS) Treatment Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

Amyotrophic lateral sclerosis (ALS) is also known as Lou Gehrig’s disease or Maladie De Charcot, it is a neurological disease that causes nerve cells to gradually break down and die.

The cause is not known in 90% to 95% of cases. The remaining 5–10% of cases are inherited from a person's parents. About half of these genetic cases are due to one of two specific genes. The underlying mechanism involves damage to both upper and lower motor neurons. The diagnosis is based on a person's signs and symptoms, with testing done to rule out other potential causes.

GlobalAmyotrophic Lateral Sclerosis (ALS) Treatment key players include Mitsubishi Tanabe Pharma, Sanofi, etc. Global top two manufacturers hold a share over 80%.

Read the full market overview

North America is the largest market, with a share about 60%, followed by Japan, and Europe, both have a share over 20 percent.

In terms of product, Edaravone (Radicava) is the largest segment, with a share over 75%. And in terms of application, the largest application is Hospital, followed by Drugs Store, etc.

This report provides an overview of the global Amyotrophic Lateral Sclerosis (ALS) Treatment market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Amyotrophic Lateral Sclerosis (ALS) Treatment and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Amyotrophic Lateral Sclerosis (ALS) Treatment revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Amyotrophic Lateral Sclerosis (ALS) Treatment market.

Amyotrophic Lateral Sclerosis (ALS) Treatment Segment by Company

Mitsubishi Tanabe Pharma

Sanofi

Mylan Pharma

Apotex

Glemark Generics

Covis Pharma

Sun Pharma

Lunan Pharma

Amyotrophic Lateral Sclerosis (ALS) Treatment Segment by Type

Riluzole

Edaravone (Radicava)

Other

Amyotrophic Lateral Sclerosis (ALS) Treatment Segment by Application

Hospital

Drugs Store

Other

Amyotrophic Lateral Sclerosis (ALS) Treatment Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Amyotrophic Lateral Sclerosis (ALS) Treatment status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Amyotrophic Lateral Sclerosis (ALS) Treatment key companies, revenue, market share, and recent developments.

3. To split the Amyotrophic Lateral Sclerosis (ALS) Treatment breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Amyotrophic Lateral Sclerosis (ALS) Treatment market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Amyotrophic Lateral Sclerosis (ALS) Treatment significant trends, drivers, influence factors in global and regions.

6. To analyze Amyotrophic Lateral Sclerosis (ALS) Treatment competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Amyotrophic Lateral Sclerosis (ALS) Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Amyotrophic Lateral Sclerosis (ALS) Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Amyotrophic Lateral Sclerosis (ALS) Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Amyotrophic Lateral Sclerosis (ALS) Treatment industry.

Chapter 3: Detailed analysis of Amyotrophic Lateral Sclerosis (ALS) Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Amyotrophic Lateral Sclerosis (ALS) Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Amyotrophic Lateral Sclerosis (ALS) Treatment in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Amyotrophic Lateral Sclerosis (ALS) Treatment Industry Trends Table 2. Amyotrophic Lateral Sclerosis (ALS) Treatment Industry Drivers Table 3. Amyotrophic Lateral Sclerosis (ALS) Treatment Industry Opportunities and Challenges Table 4. Amyotrophic Lateral Sclerosis (ALS) Treatment Industry Restraints Table 5. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Share by Company (2021-2026) Table 7. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Key Company Manufacturing Base & Headquarters Table 9. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Company, Product Type & Application Table 10. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Amyotrophic Lateral Sclerosis (ALS) Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Riluzole Table 15. Significant Companies of Edaravone (Radicava) Table 16. Significant Companies of Other Table 17. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Type (2021-2026) Table 21. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Hospital Table 23. Significant Companies of Drugs Store Table 24. Significant Companies of Other Table 25. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Application (2021-2026) Table 29. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Application (2027-2032) Table 30. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Region (2021-2026) Table 33. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Region (2027-2032) Table 35. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Market Share by Country (2021-2026) Table 38. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Market Share by Country (2027-2032) Table 40. Mitsubishi Tanabe Pharma Company Information Table 41. Mitsubishi Tanabe Pharma Business Overview Table 42. Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio Table 44. Mitsubishi Tanabe Pharma Recent Development Table 45. Sanofi Company Information Table 46. Sanofi Business Overview Table 47. Sanofi Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Sanofi Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio Table 49. Sanofi Recent Development Table 50. Mylan Pharma Company Information Table 51. Mylan Pharma Business Overview Table 52. Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio Table 54. Mylan Pharma Recent Development Table 55. Apotex Company Information Table 56. Apotex Business Overview Table 57. Apotex Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Apotex Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio Table 59. Apotex Recent Development Table 60. Glemark Generics Company Information Table 61. Glemark Generics Business Overview Table 62. Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio Table 64. Glemark Generics Recent Development Table 65. Covis Pharma Company Information Table 66. Covis Pharma Business Overview Table 67. Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio Table 69. Covis Pharma Recent Development Table 70. Sun Pharma Company Information Table 71. Sun Pharma Business Overview Table 72. Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio Table 74. Sun Pharma Recent Development Table 75. Lunan Pharma Company Information Table 76. Lunan Pharma Business Overview Table 77. Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio Table 79. Lunan Pharma Recent Development Table 80. Research Programs/Design for This Report Table 81. Authors List of This Report Table 82. Secondary Sources Table 83. Primary Sources List of Figures Figure 1. Amyotrophic Lateral Sclerosis (ALS) Treatment Product Image Figure 2. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2021-2032) & (US$ Million) Figure 4. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Riluzole Image Figure 8. Edaravone (Radicava) Image Figure 9. Other Image Figure 10. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Type (2021-2032) Figure 13. Hospital Image Figure 14. Drugs Store Image Figure 15. Other Image Figure 16. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Application (2021-2032) Figure 19. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value (2021-2032) & (US$ Million) Figure 22. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value (2021-2032) & (US$ Million) Figure 28. South America Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Riluzole
  • Edaravone (Radicava)
  • Other
Applications
  • Hospital
  • Drugs Store
  • Other
Companies covered
  • Mitsubishi Tanabe Pharma
  • Sanofi
  • Mylan Pharma
  • Apotex
  • Glemark Generics
  • Covis Pharma
  • Sun Pharma
  • Lunan Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Amyotrophic Lateral Sclerosis (ALS) Treatment Market Dynamics
  1. 2.1 Amyotrophic Lateral Sclerosis (ALS) Treatment Industry Trends
  2. 2.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Industry Drivers
  3. 2.3 Amyotrophic Lateral Sclerosis (ALS) Treatment Industry Opportunities and Challenges
  4. 2.4 Amyotrophic Lateral Sclerosis (ALS) Treatment Industry Restraints
3 Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Company
  1. 3.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Company Revenue Ranking in 2025
  2. 3.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Company (2021-2026)
  3. 3.3 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Company Ranking (2024-2026)
  4. 3.4 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Company Manufacturing Base and Headquarters
  5. 3.5 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Company Product Type and Application
  6. 3.6 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Amyotrophic Lateral Sclerosis (ALS) Treatment Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Type
  1. 4.1 Amyotrophic Lateral Sclerosis (ALS) Treatment Type Introduction
  2. 4.1.1 Riluzole
  3. 4.1.2 Edaravone (Radicava)
  4. 4.1.3 Other
  5. 4.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value by Type
  6. 4.2.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value by Type (2021-2032)
  8. 4.2.3 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Type (2021-2032)
5 Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Application
  1. 5.1 Amyotrophic Lateral Sclerosis (ALS) Treatment Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Drugs Store
  4. 5.1.3 Other
  5. 5.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value by Application
  6. 5.2.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value by Application (2021-2032)
  8. 5.2.3 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Application (2021-2032)
6 Amyotrophic Lateral Sclerosis (ALS) Treatment Regional Value Analysis
  1. 6.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value by Region (2021-2032)
  3. 6.2.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value by Region: 2021-2026
  4. 6.2.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value (2021-2032)
  7. 6.3.2 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value (2021-2032)
  10. 6.4.2 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value (2021-2032)
  16. 6.6.2 South America Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Country, 2025 VS 2032
7 Amyotrophic Lateral Sclerosis (ALS) Treatment Country-level Value Analysis
  1. 7.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value by Country (2021-2032)
  3. 7.2.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value by Country (2021-2026)
  4. 7.2.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Mitsubishi Tanabe Pharma
  2. 8.1.1 Mitsubishi Tanabe Pharma Company Information
  3. 8.1.2 Mitsubishi Tanabe Pharma Business Overview
  4. 8.1.3 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio
  6. 8.1.5 Mitsubishi Tanabe Pharma Recent Developments
  7. 8.2 Sanofi
  8. 8.2.1 Sanofi Company Information
  9. 8.2.2 Sanofi Business Overview
  10. 8.2.3 Sanofi Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Sanofi Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio
  12. 8.2.5 Sanofi Recent Developments
  13. 8.3 Mylan Pharma
  14. 8.3.1 Mylan Pharma Company Information
  15. 8.3.2 Mylan Pharma Business Overview
  16. 8.3.3 Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio
  18. 8.3.5 Mylan Pharma Recent Developments
  19. 8.4 Apotex
  20. 8.4.1 Apotex Company Information
  21. 8.4.2 Apotex Business Overview
  22. 8.4.3 Apotex Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Apotex Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio
  24. 8.4.5 Apotex Recent Developments
  25. 8.5 Glemark Generics
  26. 8.5.1 Glemark Generics Company Information
  27. 8.5.2 Glemark Generics Business Overview
  28. 8.5.3 Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio
  30. 8.5.5 Glemark Generics Recent Developments
  31. 8.6 Covis Pharma
  32. 8.6.1 Covis Pharma Company Information
  33. 8.6.2 Covis Pharma Business Overview
  34. 8.6.3 Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio
  36. 8.6.5 Covis Pharma Recent Developments
  37. 8.7 Sun Pharma
  38. 8.7.1 Sun Pharma Company Information
  39. 8.7.2 Sun Pharma Business Overview
  40. 8.7.3 Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio
  42. 8.7.5 Sun Pharma Recent Developments
  43. 8.8 Lunan Pharma
  44. 8.8.1 Lunan Pharma Company Information
  45. 8.8.2 Lunan Pharma Business Overview
  46. 8.8.3 Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio
  48. 8.8.5 Lunan Pharma Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst